Bright Peak Therapeutics to Participate in 43rd Annual J.P. Morgan Healthcare Conference

AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 6 de janeiro de 2025

Bright Peak Therapeutics, Inc.

BASEL, Switzerland and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced that Fredrik Wiklund, Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14^th, 2025, at 2:30 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference.

About Bright Peak Therapeutics
Bright Peak Therapeutics is a clinical-stage biotechnology company pioneering multifunctional immunotherapies to treat cancer. Leveraging innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is building a robust pipeline of first-in-class multifunctional molecules. The company’s lead program, BPT567, is a bifunctional PD1-IL18 immunoconjugate currently in Phase 1/2a clinical trials. With headquarters in Basel, Switzerland, and San Diego, CA, Bright Peak is backed by top-tier healthcare investors. For more information, visit www.brightpeaktx.com.

Contact:
info@brightpeaktx.com

A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire